Heather White
Directeur Technique/Scientifique/R&D chez ALBIREO PHARMA, INC.
Postes actifs de Heather White
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ALBIREO PHARMA, INC. | Directeur Technique/Scientifique/R&D | 02/03/2023 | - |
Historique de carrière de Heather White
Anciens postes connus de Heather White
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| AMICUS THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/01/2008 | - |
Schering-Plough Ltd.
 Schering-Plough Ltd. Pharmaceuticals: MajorHealth Technology Schering-Plough Ltd. manufactures and distributes pharmaceutical products. Its products include medicines for vascular diseases, oncology, opioid tendency, sexual health and virology. The company was founded on December 31, 1884 and is headquartered in Walton, the United Kingdom. | Directeur Technique/Scientifique/R&D | 01/01/1997 | - |
| IPSEN | Comptroller/Controller/Auditor | 01/01/2014 | - |
Formation de Heather White
| The University of Liverpool | Graduate Degree |
Statistiques
Internationale
| Royaume-Uni | 3 |
| Etats-Unis | 3 |
| France | 2 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 2 |
| Comptroller/Controller/Auditor | 1 |
| Director/Board Member | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| IPSEN | Health Technology |
| AMICUS THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Schering-Plough Ltd.
Schering-Plough Ltd. Pharmaceuticals: MajorHealth Technology Schering-Plough Ltd. manufactures and distributes pharmaceutical products. Its products include medicines for vascular diseases, oncology, opioid tendency, sexual health and virology. The company was founded on December 31, 1884 and is headquartered in Walton, the United Kingdom. | Health Technology |
Albireo Pharma, Inc.
 Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |
- Bourse
- Insiders
- Heather White
- Expérience